The Clinical Prognosis Of Different Antiplatelet Therapy In Patients With Acute Coronary Syndrome During Perioperative Of Percutaneous Coronary Intervention

Objective:To observe the clinical prognosis of Ticagrelor or Clopidogrel in patients with acute coronary syndrome(ACS) during perioperative of percutaneous coronary intervention(PCI). Methods :457 patients with ACS were included in our study,who selected from The heart center of the First hospital of Lanzhou University from Jan. 2014 to Apr. 2015. All the patients underwent successful PCI and divided into two groups according to Ticagrelor or Clopidogrel was used during PCI procedure. Ticagrelor was used for patients in group G1(n=222), Clopidogrel was used for patients in group G2(n=235). The MACE and bleeding rates during the follow-up period(1 month) were calculated and compared between the two groups. And observe the occurrence of Ticagrelor-related dyspnea. Results:The incidences of MACE in group G1 were lower than group G2(2.3% vs. 5.1%),and the incidences of MACE were not significantly different between the two groups(1.8% vs.0.4%,p=0.16).The incidences of non-fatal myocardial infarction and of revascularization were lower in group G1 than in group G2(0% vs.0.4%, p<0.000;0.5% vs.4.3%, p=0.008).The group G1 had higher incidences of type-1 of BARC bleeding(8.55% vs.1.28%, p<0.000). Ticagrelor-related dyspnea occurred in 43 patients. Only 16 patients(37.20%) required cessation of Ticagrelor. Conclusions: Although the rate of bleeding of Ticagrelor is higher than clopidogrel, Ticagrelor may have better clinical prognosis in patients with ACS during PCI. Few patients developed Ticagrelor-related dyspnea with only limited number of patients required treatment cessation.